Blastic plasmacytoid dendritic cell tumor treated with DVT regimen: a case report and literature review
10.3760/cma.j.cn121090-20230524-00211
- VernacularTitle:DVT方案治疗母细胞性浆细胞样树突细胞肿瘤1例报告并文献复习
- Author:
Jie SHI
1
;
Ning XU
;
Yan NIU
;
Sixun JIA
;
Chenmeng YANG
;
Meiyun FANG
Author Information
1. 大连大学附属中山医院血液科，大连 116000
- From:
Chinese Journal of Hematology
2024;45(1):86-89
- CountryChina
- Language:Chinese
-
Abstract:
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematological malignancy, there is no standard treatment and the prognosis is very poor. Affiliated Zhongshan Hospital of Dalian University report a case of 85-year-old BPDCN male patient treated with DVT regimen (decitabine combined with Venetoclax and thalidomide) and achieved complete remission. The patient with skin nodules and the pathology diagnosed BPDCN, the next generation sequencing of skin nodules showed mutations of IDH2 and ASXL1. DVT (decitabine combined with Venetoclax and thalidomide) has significant efficacy with rapid and deep remission for BPDCN, and the adverse effects is less, especially suitable for elderly patients who cannot tolerate intense chemotherapy.
